Myocardial effects of VDR activators in renal failure

Journal of Steroid Biochemistry and Molecular Biology

Volumn 121, Issue 1-2, 2010, Pages 188-192

  Mizobuchi, Masahide ^a   Nakamura, Hironori ^a   Tokumoto, Masanori ^a   Finch, Jane ^a   Morrissey, Jeremiah ^b   Liapis, Helen ^a   Slatopolsky, Eduardo ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiomyopathy; Phosphorus; Renal failure; Vitamin D

Indexed keywords

ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; PARICALCITOL; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; ERGOCALCIFEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; IMMUNOHISTOCHEMISTRY; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; UPREGULATION; UREMIA; WESTERN BLOTTING; ANIMAL; DISEASE COURSE; FIBROSIS; HEART MUSCLE; HEART VENTRICLE; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT;

RATTUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DISEASE PROGRESSION; ERGOCALCIFEROLS; FEMALE; FIBROSIS; HEART VENTRICLES; KIDNEY FAILURE, CHRONIC; MYOCARDIUM; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CALCITRIOL; RENIN-ANGIOTENSIN SYSTEM; UP-REGULATION;

EID: 77954709540     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2010.03.026     Document Type: Article

References (14)

1. Teng M., Wolf M., Lowrie E., et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N. Engl. J. Med. 2003, 349:446-456.
2. Teng M., Wolf M., Ofsthun M.N., et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J. Am. Soc. Nephrol. 2005, 16:1115-1125.
3. Kalantar-Zadeh K., Kuwaen, Regidor D., et al. Survival predictability time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006, 70:771-780.
4. Tentori F., Hunt W.C., Stidley C.A., et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2006, 70:1858-1865.
5. Dusso A., Brown A.J., Slatopolsky E. Vitamin D. Am. J. Physiol. Renal Physiol. 2005, 289:8028.
6. Fraga C., Blanco M., Vigo E., et al. Autogenesis of the vitamin D receptor in the rat heart. Histochem. Cell Biol. 2002, 117:547-550.
7. Simpson R.U., Thomas G.A., Arnold A.J. Identification of 1,25 dihydroxyvitamin D3 receptors and activities in muscle. J. Biol. Chem. 1985, 260:8882-8891.
8. Cheng S., Glenn D.J., Grigbsby L., et al. Expression of the vitamin D receptor is increased in the hypertropic heart. Hypertension 2008, 52:1160-1172.
9. Li Y.C., Kong J., Wei M., et al. 1,25 dihydroxyvitamin D3 is a negative endocrine regulator of the rennin-angiotensin system. J. Clin. Invest. 2002, 110:229-238.
10. Kong J., Li Y.C. Effect of angiotensin-converting enzyme inhibitor in vitamin D receptor null mice. Am. J. Physiol. Regul. Int. Comp. Physiol. 2003, 285:R255-R261.
11. Xiang W., Kong J., Chen S., et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac rennin-angiotensin systems. Am. J. Physiol. Endocrinol. Metab. 2005, 288:E125-E132.
12. Yuan W., Pan W., ZHeng V., et al. 1,25 dihydroxyvitamin D3 suppresses rennin gene transcription by blocking the activity of the cyclic AMP response element in the rennin gene promoter. J. Biol. Chem. 2007, 282:29821-29830.
13. Mizobuchi M., Morrissey J., Finch J., et al. Combination therapy with an angiotensin-converting enzyme inhibitor and vitamin D analog suppress the progression of renal insufficiency in the rat. J. Am. Soc. Nephrol. 2007, 18:1796-1806.
14. Husain K., Ferder L., Mizobuchi M., et al. Combination therapy with paricalcitol and enalapril ameliorates cardiac oxidative injury in uremic rats. Am. J. Nephrol. 2009, 29:1-16.